Interim analysis of Phase 1b clinical study of GT-02287, including biomarker and clinical endpoints, will be presented in oral symposiumCompany ...
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced financial results for ...
InvestorsHub on MSN
Septerna tops Q4 loss expectations as collaboration revenue lifts results
Septerna Inc. (NASDAQ:SEPN) reported a smaller-than-expected loss for the fourth quarter on Monday, posting a deficit of -$0.24 per share compared with analyst forecasts of -$0.72 per share. The ...
SOUTH SAN FRANCISCO, Calif. - On Monday, Septerna Inc. (NASDAQ:SEPN) reported a fourth quarter loss of -$0.24 per share, beating analyst estimates of -$0.72 per share. Revenue reached $24.1 million ...
For years, a protein inside our cells has quietly powered billions of dollars' worth of cancer drugs. Now a team of ...
(Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today highlighted pipeline progress and anticipated milestones and ...
Direct multi-KRAS inhibitors, QTX3034 and QTX3544, exhibit potent activity against established and novel resistance mechanisms to daraxonrasibin KRAS-mutated colorectal cancer cells - ...
Allosteric Bioscience, Inc. is delineating the Molecular Mechanism of Aging and Longevity with the goal of optimizing the aging process and extending longevity. It is utilizing Genomics, Biology, ...
Allosteric Bioscience, Inc. is utilizing Genetics, Genomics, Systems Biology, Quantum Computing, Advanced Proprietary AI and Proprietary Molecular Technologies for understanding and controlling the ...
HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, allosteric ...
Septerna has reported positive past Phase 1 results for SEP-631, an oral negative allosteric modulator of MRGPRX2, showing robust target engagement, functional pathway blockade, and tolerability ...
Beginning a new drug discovery collaboration using Congruence’s globally recognized Revenir™ platform for the creation of small molecule modulatorsExpanded collaboration into Ono’s other priority ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results